A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial

Joyce M. van Dodewaard-de Jong,John M.H. de Klerk,Haiko J. Bloemendal,Daniela E. Oprea-Lager,Otto S. Hoekstra,H. Pieter van den Berg,Maartje Los,Aart Beeker,Marianne A. Jonker,Joe M. O’Sullivan,Henk M.W. Verheul,Alfons J.M. van den Eertwegh

A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial

2017

Joyce M. van Dodewaard-de Jong
John M.H. de Klerk
Haiko J. Bloemendal
Daniela E. Oprea-Lager
Otto S. Hoekstra
H. Pieter van den Berg
Maartje Los
Aart Beeker
Marianne A. Jonker
Joe M. O’Sullivan
Henk M.W. Verheul
Alfons J.M. van den Eertwegh

Background Rhenium-188-HEDP is a beta-emitting radiopharmaceutical used for palliation of metastatic bone pain. We investigated whether the addition of rhenium-188-HEDP to docetaxel/prednisone improved efficacy of chemotherapy in patients with CRPC.

Keywords:

Medicine
Prednisone
Phases of clinical research
Castration
Prostate cancer
Oncology
Metastatic bone pain
Chemotherapy
Internal medicine
Docetaxel
castration resistant
Etidronic acid
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations